Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immunovant, Inc.    IMVT


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shareholder Alert: Robbins LLP Announces That Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) is Being Sued for Misleading Shareholders

02/23/2021 | 05:26pm EST

Shareholder rights law firm Robbins LLP announces that a purchaser of Immunovant, Inc. (NASDAQ: IMVT) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 2, 2019 and February 1, 2021. Immunovant is a clinical-stage biopharmaceutical company. The Company is developing IMVT-1401, which is in Phase IIa clinical trials for the treatment of Graves' ophthalmopathy. The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia.

If you suffered a loss due to Immunovant, Inc.'s misconduct, click here.

Immunovant, Inc. (IMVT) Misled Shareholders About the Viability of its Drug Candidate IMVT-1401

According to the complaint, on September 29, 2019, Health Sciences Acquisitions Corporation (HSAC), then a special purpose acquisition company, entered into an agreement with Immunovant Sciences Ltd., a private biopharmaceutical company, to effect a merger between the two entities. As a result of the merger, HSAC acquired all shares of Immunovant Sciences and Immunovant Sciences became a wholly owned subsidiary of HSAC. HSAC then changed its name to Immunovant, Inc.

During the relevant period, defendants made false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Immunovant Sciences prior to the merger; (ii) HSAC ignored safety issues associated with Immunovant Science's drug candidate IMVT-1401; and (iii) IMVT-1401 was less safe than the Company had led investors to believe, which foreseeably diminished its prospects for regulatory approval, commercial viability and profitability.

On February 2, 2021, Immunovant issued a press release announcing "a voluntary pause of dosing in its original clinical trials for IMVT-1401," and disclosed that it "has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low density lipoproteins] levels in IMVT-1401-treated patients." On this news, Immunovant's stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021.

If you purchased shares of Immunovant, Inc. (IMVT) between October 2, 2019 and February 1, 2021, you have until April 20, 2021, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Immunovant, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

© Business Wire 2021
All news about IMMUNOVANT, INC.
02/26IMMUNOVANT : ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Immunovant, Inc. f/k/..
02/25SHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class A..
02/25BREAKING ALERT : ROSEN, A TOP RANKED LAW FIRM, Encourages Immunovant, Inc. f/k/a..
02/25GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces the..
02/25IMVT INVESTOR FILING DEADLINE : Bernstein Liebhard LLP Reminds Investors of the ..
02/24INVESTOR ALERT : Law Offices of Howard G. Smith Announces the Filing of a Securi..
02/24THE LAW OFFICES OF FRANK R. CRUZ : Announces the Filing of a Securities Class Ac..
02/23SHAREHOLDER ALERT : Robbins LLP Announces That Immunovant, Inc. f/k/a Health Sci..
02/23THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation of Immunovant, Inc. f..
02/23GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Inv..
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -112 M - -
Net cash 2021 388 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Capitalization 1 546 M 1 546 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 42
Free-Float 39,6%
Duration : Period :
Immunovant, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOVANT, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 11
Average target price 38,55 $
Last Close Price 15,78 $
Spread / Highest target 249%
Spread / Average Target 144%
Spread / Lowest Target 64,8%
EPS Revisions
Managers and Directors
Peter Salzmann Chief Executive Officer & Director
Pamela Yanchik Connealy Chief Financial Officer
Frank M. Torti Chairman
Julia G. Butchko Chief Development & Technology Officer
Michael Elliott Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOVANT, INC.-65.84%1 546
MODERNA, INC.42.03%58 715
LONZA GROUP AG2.64%47 991
CELLTRION, INC.-17.13%37 780
SEAGEN INC.-13.72%27 191